Welcome to SIR 2021

Engage with Boston Scientific Senior Leadership, ask questions, and learn more about our future investments in Interventional Oncology!

Key Sessions at SIR

Boston Scientific is pleased to present a symposium highlighting three important studies for the use of Y-90 glass microspheres – LEGACY, DOSISPHERE-01 and TARGET.

SIR 2021 | March 23 | 2:10-2:50 PM EST

Monday, March 22 | 10:00 AM – 10:09 AM

Featured Abstract - Clinical predictors of Yttrium-90 uptake in hepatocellular carcinoma: towards personalized dosimetry to maximize response to therapy.

Tuesday, March 23 | 10:20 – 10:29 AM

34 - Planar Scintigraphy Overestimates Hepatopulmonary Shunt Fractions Compared to Quantitative SPECT/CT (utilizing Simplicit90Y dosimetry software).

Wednesday, March 24 | 11:15 AM – 11:30 AM

Y-90 Radioembolization to the Prostate Gland: Proof of Concept in a Canine Model and Clinical Translation.

2021 SIR Excellence in Innovation Award.

(445) Dose distribution in radioembolization: A comparison between glass and resin microspheres.

Analyses from the Late Breaking TARGET Study - image.

TheraSphere receives FDA Approval!

After 20 years as a humanitarian exemption device (HDE), the FDA grants TheraSphere pre-market approval, making TheraSphere the only Y-90 therapy indicated for HCC. This means institutional review board (IRB) approval of TheraSphere is no longer required by the FDA.

Learn More About TheraSphere ›